Search Results
Your search for early matches 10493 pages
Showing 3151 - 3200A Junior High School Teacher Sparks a Love for Science
Peter Marks, MD, PhD, Director of the U.S. Food and Drug Administration (FDA)’s Center for Biologics Evaluation and Research (CBER), was born in Brooklyn, New York, near Sheepshead Bay—an area named for the Sheepshead, a fish that can no longer be found in the waters that frame the neighborhood....
A Doctor’s Daughter Becomes a Pioneer in Cancer Survivorship
Although quality of life has been an implicit medical outcome since the time of Hippocrates, integrating the explicit effort to assess the effects of cancer treatment on the patient’s quality—and not quantity—of life was spearheaded by dedicated pioneers. One such trailblazer is Patricia A. Ganz,...
New FDA-Approved Oncology Drugs and Label Updates Between May 8, 2020, and May 8, 2021
Over the past year (May 2020–May 2021), the U.S. Food and Drug Administration (FDA) approved and expanded indications for many drugs related to the treatment of different types of cancers and adverse events. The new approvals and accelerated approvals are listed below. PEMBROLIZUMAB (KEYTRUDA) in...
A Love for Surgery Underpins a Career Devoted to Patients With Pancreatic Cancer
There are few, if any, more difficult clinical challenges than pancreatic cancer, a disease that continues to confound the oncology community’s quest for cure. Yet, incremental progress and unflagging optimism drive the way forward, thanks to the researchers and clinicians who have dedicated their...
Organizations Issue Statement Encouraging Return to HPV Vaccination
Doctors and scientists across America at National Cancer Institute (NCI)-designated cancer centers and other organizations recently issued a joint statement urging the nation’s health-care systems, physicians, parents, children, and young adults to get human papillomavirus (HPV) vaccination back on ...
Noninvasive Imaging Biomarker and Pathologic Complete Response to Neoadjuvant Pertuzumab/Trastuzumab in HER2-Positive Breast Cancer
As reported in the Journal of Clinical Oncology by Roisin M. Connolly, MD, and colleagues, updated results of the phase II TBCRC026 trial indicate an association of early F-18 fluorodeoxyglucose positron-emission tomography/computed tomography (F-18 FDG PET/CT) maximum standardized uptake value...
Neoadjuvant Chemotherapy De-escalation Using F-18 FDG-PET Response–Based Strategy in HER2-Positive Breast Cancer
In the European phase II PHERGain study reported in The Lancet Oncology, Pérez-García et al found that an F-18 fluorodeoxyglucose positron-emission tomography (F-18 FDG-PET) response–based strategy may be able to identify patients with HER2-positive early breast cancer who may benefit from...
Neoadjuvant Durvalumab With vs Without Stereotactic Body Radiotherapy in Early-Stage NSCLC
In a single-center phase II trial reported in The Lancet Oncology, Nasser K. Altorki, MD, and colleagues found that neoadjuvant durvalumab plus stereotactic body radiotherapy (SBRT) resulted in a markedly higher major pathologic response rate vs durvalumab alone in patients with early-stage...
FDA Approves Piflufolastat F-18 Injection, a PSMA PET Imaging Agent, for the Detection of Metastatic or Recurrent Prostate Cancer
On May 27, the U.S. Food and Drug Administration (FDA) approved piflufolastat F-18 injection (Pylarify), an F-18–labeled prostate-specific membrane antigen (PSMA)-targeted positron-emission tomography (PET) imaging agent, to identify suspected metastasis or recurrence of prostate cancer. This is...
Use of Systemic Therapy at the End of Life in Patients With Cancer: Effect of Approval of Immunotherapies
In a study reported in JCO Oncology Practice, Khaki et al found that although the use of anticancer systemic therapy during the last 30 days of life in patients with cancer has decreased overall since the first approval of a PD-1 immune checkpoint inhibitor, the use of PD-1 or PD-L1 inhibitors...
Lustgarten Foundation–AACR Career Development Awards for Pancreatic Cancer Research
Dannielle Engle, PhD, of the Salk Institute for Biological Studies, and Avery D. Posey, PhD, of the Perelman School of Medicine at the University of Pennsylvania, were announced at the American Association for Cancer Research (AACR) Annual Meeting 2021 as the inaugural recipients of the Lustgarten...
Enduring Cancer and Its Treatment With Resilience and Humor
Most cancer memoirs have a similar thread: life suddenly interrupted by arguably the three most dreaded words in the English language, “You have cancer.” Readers anticipate the high-drama uncertainty leading to diagnosis, treatment, and hopefully survivorship, with multiple human storylines woven...
Coagulopathy and COVID-19 Infection
“Life is short, art long, opportunity fleeting, experience treacherous, judgment difficult.” —Hippocrates To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the...
Balancing a Reverence for Life With a Belief That Patients Have a Right to a Dignified Death
The U.S. right-to-die movement took root in the mid-1970s, when Derek Humphry helped his wife, who was dying of breast cancer, take her own life. Five years later, Mr. Humphry founded the Hemlock Society, the first right-to-die organization in the United States,1 and set off a firestorm of...
An Epiphany During Fellowship Led to a Career in Geriatric Oncology for Heidi D. Klepin, MD, MS
Geriatric oncologist Heidi D. Klepin, MD, MS, was born and reared in Pearl River, a hamlet on the west side of the Hudson River in New York. “My parents are German immigrants who came to the United States in the 1960s looking for prospects. Growing up in post-war Germany, neither had the...
Improving Prediction of Risk for 10-Year Left-Ventricular Systolic Dysfunction in Survivors of Childhood Cancer
In a Dutch study reported in JACC: CardioOncology, Jan M. Leerink, PhD candidate, of Amsterdam UMC, University of Amsterdam Department of Clinical and Experimental Cardiology, and colleagues found that the addition of ejection fraction measurement at the time of first surveillance echocardiogram...
Sloan Kettering Institute Researchers Awarded 2021 Kravis Women in Science Endeavor Fellowship Grants
Memorial Sloan kettering Cancer Center (MSK) announced that Sloan Kettering Institute (SKI) researchers Regina Bou Puerto and Mijin Kim, PhD, have been named 2021 Marie-Josée Kravis Women in Science Endeavor (Kravis WiSE) fellowship grant recipients. The Kravis WiSE initiative, created in 2020,...
Celebrating 50 Years of Cancer Progress: The International View
Although the National Cancer Act of 1971 has resulted in tremendous advances in cancer research, which have led to sharp declines in cancer mortality in the United States—from 1991 to 2018, there has been a 31% decrease in overall cancer death rates—and more than 17 million cancer survivors,1 much...
Nima Sharifi, MD, Receives 2021 AACR–Waun Ki Hong Award in Translational and Clinical Cancer Research
THE AMERICAN ASSOCIATION for Cancer Research (AACR) has recognized Nima Sharifi, MD, with the 2021 AACR–Waun Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research. Dr. Sharifi is Director of the Center for Genitourinary Malignancies Research at Lerner Research...
Ton Schumacher, PhD, FAACR, Receives 2021 AACR-CRI Lloyd J. Old Award in Cancer Immunology
THE AMERICAN ASSOCIATION for Cancer Research (AACR) recognized Ton Schumacher, PhD, FAACR, with the 2021 AACR-CRI Lloyd J. Old Award in Cancer Immunology during the virtual AACR Annual Meeting 2021 in April. The award recognizes an active scientist whose outstanding and innovative research has made ...
FDA ODAC Meeting Focuses on ‘Dangling’ Accelerated Approvals of Anti–PD-1/PD-L1 Antibodies
In a perspective in The New England Journal of Medicine, Julia A. Beaver, MD, and Richard Pazdur, MD, of the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE), discussed issues surrounding “dangling” accelerated approvals of anti–PD-1/PD-L1 antibodies—ie, approvals for...
Inequities in Breast Cancer Screening During the COVID-19 Pandemic
Breast cancer screening took a sizeable hit during the COVID-19 pandemic, according to new research showing that the number of screening mammograms completed in a large group of women living in Washington state plummeted by nearly half. Published by Amram et al in JAMA Network Open, the study...
ASCO Honors 2021 Special Awards Recipients
Researchers, patient advocates, and global oncology leaders who have worked to reshape cancer care around the world are among the recipients of ASCO’s Special Awards—the Society’s highest honors—and the Women Who Conquer Cancer Mentorship Awards from Conquer Cancer, the ASCO Foundation. “The...
Drive, Curiosity, and a Love of Science: One Nurse’s Road to a Leadership Role in Oncology
For this installment of the Living a Full Life series, guest editor Jame Abraham, MD, spoke with Deborah Watkins Bruner, RN, PhD, FAAN, noted for her work in patient-reported outcomes, symptom management, and comparative effectiveness of radiotherapy modalities. Her current research is focused on...
Cognitive Performance at Baseline and Over Time in Infants Treated for Brain Tumors
In a prospective longitudinal trial reported in the Journal of Clinical Oncology, Ali et al found that infants treated for central nervous system (CNS) malignancies had baseline intellectual quotient (IQ) and parent-reported working memory and adaptive functioning worse than normative expectations; ...
Machine Learning–Based Algorithm May Predict Short-Term Mortality in Patients With Cancer and Prompt Serious Illness Conversations
Although most patients with terminal cancer, 87%, have end-of-life conversations with clinicians about their goals and preferences for care, on average, these discussions happen just 1 month before death and most often occur in acute care settings with clinicians who are not their treating...
NCCN Clinical Practice Guidelines in Oncology: 2021 Updates
In 1996, the National Comprehensive Cancer Network® (NCCN®) published its first set of Clinical Practice Guidelines in Oncology®, covering eight tumor types. Guidelines are now published for more than 60 tumor types and topics. During the NCCN’s 26th Annual Conference, which was held virtually...
AACR to Recognize the St. Baldrick’s Foundation–SU2C Pediatric Cancer Dream Team With 2021 Team Science Award
The American Association for Cancer Research (AACR) will recognize the St. Baldrick’s Foundation–Stand Up To Cancer (SU2C) Pediatric Cancer Dream Team with the 2021 AACR Team Science Award. In early 2013, the St. Baldrick’s Foundation and SU2C collaborated to create a Pediatric Cancer Dream Team...
Oncolytic Virotherapy Achieves Early Signs of Success in High-Grade Gliomas
Treatment with genetically engineered oncolytic herpes simplex virus type 1 (HSV-1) G207 alone or with radiation resulted in encouraging outcomes in a small study of pediatric patients with high-grade glioma. In a phase I trial, responses were observed in 11 of 12 children, and median overall...
Equitable Cancer Care: Steps Toward Meaningful Change
As President-Elect of ASCO, you are asked to choose a theme for your presidency. This can be a daunting task, as the theme will not only shape the discourse of your presidency, but also, more importantly, that of the Society. The subject should be one that reflects the needs of the cancer community ...
ASCO’s President-Elect Focuses on Advancing Equitable Cancer Care Through Innovation
Internationally renowned for his pioneering research in combining high-dose radiation therapy and chemotherapy in the treatment of locally advanced head and neck cancer to improve patient survival, ASCO’s President-Elect Everett E. Vokes, MD, FASCO, is dedicating his tenure as President to...
Study Investigates Nongenetic Factors Linked to Development of Early-Onset Colorectal Cancer
Early-onset colorectal cancer incidence rates in the United States have nearly doubled between 1992 and 2013—up from 8.6 to 13.1 per 100,000 individuals—with most of that increase due to early-onset cancers of the rectum. A new study published by Archambault et al in JNCI Cancer Spectrum focused on ...
Fuzuloparib Maintenance Therapy Improves Progression-Free Survival in Patients With Recurrent Ovarian Cancer
A new poly (ADP-ribose) polymerase (PARP) inhibitor could soon be joining an already crowded treatment landscape in ovarian cancer, according to data presented at the Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women’s Cancer, which was held virtually.1 Results of the phase III...
American Cancer Society Releases Report on Cancer Prevention and Screening
An American Cancer Society (ACS) review of cancer prevention and early detection measures for 2018 and 2019 in the United States shows mixed progress. Smoking prevalence during this time was at an historic low, partly because most people who ever smoked have quit. However, obesity rates remained...
Standard Multigene Testing Could Detect More Hereditary Cancer Syndromes in Patients With Colorectal Cancer
Up to 38.6% of people with colon cancer who have a hereditary cancer syndrome—including 6.3% of those with Lynch syndrome—could have their conditions remain undetected with current universal tumor-screening methods, and at least 7.1% of people with colorectal cancer have an identifiable inherited...
Heather A. Wakelee, MD, on NSCLC: Atezolizumab vs Best Supportive Care After Chemotherapy
Heather A. Wakelee, MD, of Stanford University Medical Center, discusses the primary disease-free survival results of IMpower010, a phase III study that compared adjuvant atezolizumab vs best supportive care after adjuvant chemotherapy in patients with early-stage resected non–small cell lung...
Increased PSA Screening Linked to Lower Risk of Advanced Prostate Cancer at Diagnosis and Death From the Disease in Younger Black Patients
Younger Black men undergoing frequent prostate-specific antigen (PSA) screening appear to have both a lower risk of metastasis at the time of prostate cancer diagnosis and of fatal disease, according to data from an observational study by Qiao et al presented at a presscast in advance of the 2021...
Does Adjuvant Atezolizumab Extend Disease-Free Survival in Patients With Resected Early-Stage NSCLC?
Patients with resected early-stage non–small cell lung cancer (NSCLC) who received the PD-L1 inhibitor atezolizumab following cisplatin-based chemotherapy had a 34% reduction in the risk of disease recurrence compared with best supportive care, according to the results from the phase III IMpower010 ...
Study Finds Income Eligibility Limits for Medicaid May Be Associated With Worse Long-Term Survival Among Newly Diagnosed Patients With Cancer
A study investigating the association between state Medicaid income eligibility limits and long-term survival among newly diagnosed patients with cancer has found that patients living in states with lower Medicaid income eligibility limits had worse long-term survival compared with patients living...
USPSTF Issues New Recommendation Statement on Colorectal Cancer Screening
Prompted by a rise in cases of colorectal cancer in people younger than 50, the U.S. Preventive Services Task Force (USPSTF) has recommended that individuals at average risk for the disease begin screening exams at age 45 instead of the traditional age of 50. The guideline changes, published in...
Risk of Second Cancer by Hormone Receptor Status Among Breast Cancer Survivors
A new study has found breast cancer survivors in general have higher risk of new cancer diagnosis compared to healthy individuals. The article, published by Hyuna Sung, PhD, and colleagues in the journal Cancer, stated that compared to the general population in the United States, the risk of new...
Longitudinal Evaluation of Functioning in Children With Retinoblastoma
In a single-institution study reported in the Journal of Clinical Oncology, Willard et al found that improvements in cognitive and adaptive function were observed between ages 5 and 10 years in many children with retinoblastoma, with scores by age 10 generally being within normal limits. Poorer...
Comparison of Adjuvant Trastuzumab Courses for Early HER2-Positive Breast Cancer
We'll start off with an analysis of 9 weeks vs 1 year of adjuvant trastuzumab for patients with early HER2-positive breast cancer. Then, we’ll review a retrospective cohort study that aimed to quantify cancer screening deficits in the United States associated with the COVID-19 pandemic.
Abemaciclib-Associated Adverse Events: Safety Analysis of monarchE
Treatment with abemaciclib, an orally available inhibitor of CDK4/6, has been associated with venous thromboembolic events (VTE), elevated aminotransferases (EAT), and interstitial lung disease (ILD). Although more episodes of VTE, EAT, and ILD were reported in patients receiving abemaciclib plus...
Frail Patients With Newly Diagnosed Multiple Myeloma: Triplet Regimen
In the phase II Hovon 143 trial reported in the Journal of Clinical Oncology, Stege et al found that a regimen of ixazomib, daratumumab, and low-dose dexamethasone (Ixa-Dara-dex) was associated with a high response rate in frail patients with newly diagnosed multiple myeloma, but also a high rate...
Disparities in Enrollment Into Electronic Health Record Patient Portals for Oncology Patients
In a single-institution retrospective study reported in a research letter in JAMA Oncology, Sinha et al found disparities in electronic health record (EHR) patient portal enrollment according to age, sex, race/ethnicity, and primary language among oncology patients. Study Details The study involved ...
Effect of Publication of the LACC Trial on Use of Minimally Invasive Surgery for Cervical Cancer
The Laparoscopic Approach to Cervical Cancer (LACC) trial, reported in November 2018, showed poorer disease-free and overall survival with minimally invasive vs open radical hysterectomy for early-stage cervical cancer. In a study recently reported in a letter in The New England Journal of...
Cardiac Safety, Efficacy of Neoadjuvant Pertuzumab/Trastuzumab for Early-Stage HER2-Positive Breast Cancer
Long-term cardiac safety and efficacy have been confirmed for the combination of pertuzumab plus trastuzumab in patients with early-stage HER2-positive breast cancer, according to the final analysis of the phase II BERENICE trial reported by Chau T. Dang, MD, and colleagues at the ESMO Breast...
Stage IV PD-L1–High Non–Small Cell Lung Cancer: Immunotherapy Alone or With Chemotherapy?
Except in patients with no smoking history, the addition of chemotherapy to immunotherapy does not add benefit as a first-line treatment in patients with stage IV nonsquamous non–small cell lung cancer (NSCLC) and high expression of PD-L1, according to real-world experience. Outcomes from the U.S. ...
Incidence of Interstitial Lung Disease Related to Trastuzumab Deruxtecan-nxki in Patients With HER2-Positive Metastatic Breast Cancer
Drug-related interstitial lung disease occurred in less than 16% of patients with HER2-positive metastatic breast cancer following treatment with trastuzumab deruxtecan-nxki (T-DXd) at the approved dose of 5.4 mg/kg. In addition, the majority of these cases were classified as grade 1 or 2,...
